XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Segment and Related Information
 6 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Segment and Related Information SEGMENT AND RELATED INFORMATION
The Company’s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. The Company’s operating segments have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).
(in millions)DiagnosticsOtherTotal
Transition Period Ended December 31, 2020:
Revenues$271.7 $28.1 $299.8 
Depreciation and amortization33.5 2.3 35.8 
Segment operating loss(1.4)(86.4)(87.8)
Fiscal Year Ended June 30, 2020:
Revenues$593.5 $45.1 $638.6 
Depreciation and amortization68.2 3.8 72.0 
Segment operating loss(82.4)(149.3)(231.7)
Fiscal Year Ended June 30, 2019:
Revenues$789.4 $61.7 $851.1 
Depreciation and amortization67.7 5.3 73.0 
Segment operating income (loss)133.3 (125.7)7.6 
Fiscal Year Ended June 30, 2018:
Revenues$690.4 $53.3 $743.7 
Depreciation and amortization49.2 5.2 54.4 
Segment operating income (loss)142.6 (20.7)121.9 
Transition Period Ended December 31, Years Ended June 30,
(in millions)2020202020192018
Total operating income (loss) for reportable segments$(87.8)$(231.7)$7.6 $121.9 
Unallocated amounts:
Interest income0.7 3.0 3.2 1.8 
Interest expense(5.8)(10.8)(12.0)(3.2)
Other(1.2)16.2 1.2 (0.4)
Income (loss) from operations before income taxes(94.1)(223.3)— 120.1 
Income tax benefit(41.0)(23.7)(4.4)(13.0)
Net income (loss)(53.1)(199.6)4.4 133.1 
Net loss attributable to non-controlling interest— (0.1)(0.2)(0.2)
Net income (loss) attributable to Myriad Genetics, Inc stockholders
$(53.1)$(199.5)$4.6 $133.3 
The following table sets forth a comparison of balance sheet assets by operating segment:
December 31,June 30,
(in millions) 202020202019
Net equipment, leasehold improvements and property:
Diagnostics$23.0 $23.9 $25.7 
Other17.7 13.1 31.6 
Total$40.7 $37.0 $57.3 
Total assets less cash, cash equivalents, and marketable investment securities:
Diagnostics$994.0 $1,002.8 $1,215.6 
Other253.1 147.0 155.3 
Total$1,247.1 $1,149.8 $1,370.9 
The following table reconciles assets by geographical region to total assets:
December 31,June 30,
(in millions)202020202019
Net equipment, leasehold improvements and property:
United States$38.4 $35.4 $36.0 
Rest of world2.3 1.6 21.3 
Total$40.7 $37.0 $57.3 
Total assets:
United States$1,190.3 $1,097.2 $1,265.8 
Rest of world56.8 52.6 105.1 
Total assets by segment and geographical region$1,247.1 $1,149.8 $1,370.9 
Cash, cash equivalents, and marketable investment
securities (1)		171.7 254.8 191.8 
Total$1,418.8 $1,404.6 $1,562.7 
(1)The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments.
The following table reconciles revenue by geographical region to total revenue:
Transition Period Ended December 31,Years Ended June 30,
(in millions)2020202020192018
United States$275.4 $596.2 $805.4 $700.5 
Rest of world24.4 42.4 45.7 43.2 
Total revenue$299.8 $638.6 $851.1 $743.7